drugset / Trial / NCT05507242
Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD
Phase 2
Recruiting
80 enrolled
Asger Sverrild
AstraZeneca · collabUniversity Hospitals, Leicester · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.
Timeline
- Start
- 2022-10-25
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | 210 mg | Subcutaneous |